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Evidence from routine clinical practice: 
EMPRISE provides a new perspective on CVOTs
Guntram Schernthaner1*†, Avraham Karasik2*†, Agnė Abraitienė3, Alexander S. Ametov4, Zsolt Gaàl5, 
Janusz Gumprecht6, Andrej Janež7, Susanne Kaser8, Katarina Lalić9, Boris N. Mankovsky10, 
Evgeny Moshkovich11, Marju Past12, Martin Prázný13, Gabriela Radulian14, Lea Smirčić Duvnjak15, Ivan Tkáč16 
and Kārlis Trušinskis17
Abstract 
EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant car-
dioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular disease. To assess 
the impact of empagliflozin in routine clinical practice, the ongoing EMPRISE study is collecting real-world evidence 
to compare effectiveness, safety and health economic outcomes between empagliflozin and DPP-4 inhibitors. A 
planned interim analysis of EMPRISE was recently published, confirming a substantial reduction in hospitalisation for 
heart failure with empagliflozin across a diverse patient population. In this commentary article, we discuss the new 
data in the context of current evidence and clinical guidelines, as clinicians experienced in managing cardiovascular 
risk in patients with T2D. We also look forward to what future insights EMPRISE may offer, as evidence is accumulated 
over the next years to complement the important findings of EMPA-REG OUTCOME.
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Introduction
Cardiovascular (CV) outcomes are now recognised by 
international guidelines as an important consideration in 
treatment choice for patients with type 2 diabetes (T2D) 
and CV disease (CVD) [1–6]. This is an exciting devel-
opment, which follows the discovery from CV outcomes 
trials (CVOTs) that some antidiabetic agents have a car-
dioprotective effect in at-risk patients [7–10].
The first CVOT to show cardioprotection was EMPA-
REG OUTCOME, in  which empagliflozin rapidly 
reduced the risk of hospitalisation for heart failure (HHF) 
and CV death compared with placebo, independently of 
glycaemic control [11]. Despite the clinical importance of 
this finding, the underlying mechanism (or mechanisms) 
remains a matter of speculation and debate, with roles 
postulated for processes ranging from inflammation, 
oxidative stress and ionic exchange in the myocardium 
[12] to blood viscosity and wall shear stress in the carotid 
arteries [13].
CVOTs have now been completed for multiple agents 
in the SGLT2 inhibitor, GLP-1 receptor agonist and 
DPP-4 inhibitor classes; among these, cardioprotec-
tive effects have been reported for all SGLT2 inhibitors 
investigated (although not consistently across differ-
ent outcomes) and, in addition, for some GLP-1 recep-
tor agonists [14]. Such paradigm-shifting data can pose 
a challenge for clinicians, who must integrate learnings 
from a proliferating number of clinical studies into rou-
tine clinical practice, where patients and conditions are 
typically more diverse than the tightly controlled cohorts 
seen in randomised controlled trials (RCTs) such as 
CVOTs. Efforts are now underway to collect real-world 
evidence (RWE) that may help to bridge this gap, pro-
viding insights into how beneficial CV effects seen in 
CVOTs are reflected in real-world populations and eve-
ryday clinical decision-making scenarios [15].
Open Access
Cardiovascular Diabetology
*Correspondence:  guntram.schernthaner@meduniwien.ac.at; 
karasik@post.tau.ac.il
†Guntram Schernthaner and Avraham Karasik contributed equally to this 
work
1 Medical University of Vienna, Vienna, Austria
2 Sheba Medical Center and Tel Aviv University, Tel Aviv, Israel
Full list of author information is available at the end of the article
Page 2 of 9Schernthaner et al. Cardiovasc Diabetol          (2019) 18:115 
EMPRISE is an ongoing RWE study of data collected 
from US healthcare databases, comparing outcomes in 
patients newly initiated with empagliflozin vs DPP-4 
inhibitors [16]. The study will complement the findings 
of EMPA-REG OUTCOME with routine clinical practice 
data that encompasses a more diverse patient population, 
including a broader spectrum of CV risk, and an active 
comparator that prescribers currently use in a similar 
position to empagliflozin in the treatment pathway [16]. 
Over 5 years, EMPRISE will enrol approximately 200,000 
patients, and generate insights on a wide range of effec-
tiveness, safety and health economic outcomes [16].
Recently, a first interim analysis of EMPRISE was pub-
lished, covering HHF outcomes among ~ 35,000 patients 
in the time period from August 2014 through Septem-
ber 2016 (~ 33,000 in the primary analysis, which looked 
only at a single DPP-4 inhibitor, sitagliptin) [16]. Despite 
a short mean follow-up time of 5.3  months in the early 
results to emerge from EMPRISE, the data are very 
encouraging in confirming a HHF benefit in patients 
receiving empagliflozin [16].
We recently convened as a group of experts from Cen-
tral and Eastern Europe to discuss the newly described 
EMPRISE study, together with the results of its first 
interim analysis, from the perspective of our own knowl-
edge and clinical experience on managing CV risk in 
patients with T2D. In this Commentary article, we sum-
marise our discussions, considering the role for RWE in 
supporting CVOTs in clinical decision making, and plac-
ing the findings from the first interim EMPRISE analy-
sis into the context of EMPA-REG OUTCOME, other 
SGLT2 inhibitor CVOTs and international guidelines. 
We believe that these insights will be useful for clinicians 
from our region and beyond who wish to assess the evi-
dence for optimising treatment for their patients in rou-
tine clinical practice.
RWE as a complement to CVOTs
SGLT2 inhibitor CVOTs such as EMPA-REG OUT-
COME have yielded impressive results, with HHF reduc-
tions across the class and CV death outcomes with 
empagliflozin carrying sufficient weight to influence 
major international diabetology and cardiology guide-
lines [1–6]. New recommendations guided by CVOTs 
include an early consideration of CV risk and preference 
for an agent with proven CV benefit as a first-add on to 
metformin in an atherosclerotic CVD setting (prefer-
ring empagliflozin or liraglutide) [1–3, 6] or an SGLT2 
inhibitor as a first add-on to metformin in a HF setting 
[1–3, 5] (Fig. 1). However, numerous gaps in our knowl-
edge of CV outcomes in T2D remain, and we believe that 
RWE studies can have a role here, by complementing 
CVOTs with supporting evidence where data generation 
in a RCT would not be feasible. It is welcome that sev-
eral completed and ongoing studies are now providing 
such opportunities to complement CVOTs with RWE on 
SGLT2 inhibitors [17].
EMPRISE as a complementary study to EMPA‑REG 
OUTCOME
EMPRISE is a large-scale RWE study specifically under-
taken to assess whether the CV effectiveness of empa-
gliflozin observed in EMPA-REG OUTCOME [7] can 
be confirmed in routine clinical practice [16]. The study 
uses propensity score (PS) matching to compare patients 
newly initiated on empagliflozin with those newly initi-
ated on a DPP-4 inhibitor, which echoes a treatment 
choice often faced in the management of T2D [16].
Data collection is currently ongoing from 3 large US 
databases (from two commercial insurers and Medicare 
fee-for-service), with a target cohort size of ~ 200,000 
patients over 5 years by study completion [16]. Each data-
base has a different strength: MarketScan provides the 
largest number of patients; Optum is the most enriched 
for records with laboratory data; and Medicare mainly 
represents elderly patients, who have low commercial 
insurance coverage [16, 18]. PS matching ensures that 
outcomes are captured between comparable patients, 
with each individual in the empagliflozin arm matched 
with a counterpart in the comparator arm using more 
than 140 covariates [16] (Table 1).
We see several benefits to EMPRISE as an opportunity 
to generate evidence that is beyond the scope of CVOTs: 
outcomes in a more diverse patient population (both 
with and without clinical evidence of CVD); a compara-
tor that is more relevant than placebo to clinical practice 
(DPP-4 inhibitors, in keeping with a treatment choice we 
commonly face in our clinical practice); health economic 
outcomes; and a larger cohort for the study of safety out-
comes [16].
We recognise that extensive efforts have been made in 
the study design to avoid bias and minimise confounding 
(Table  1), although it must be emphasised that residual 
confounding cannot be excluded, as treatment choices 
are open label and non-randomised [16]. One possible 
source of bias that has been debated as a factor in previ-
ous RWE studies with SGLT2 inhibitors is the potential 
phenomenon of immortal time bias [19–21], which may 
occur when a different positioning in the treatment path-
way is not accounted for in the study design. However, 
EMPRISE convincingly addresses these concerns in three 
ways. First, all patients who had previously taken either 
class of agent (SGLT2 inhibitor or DPP-4 inhibitor) were 
excluded [16]. Second, an active comparator was chosen 
(sitagliptin) that is similarly positioned to empagliflo-
zin in the treatment pathway [16]. Third, PS matching 
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included relevant variables to control for immortal time 
bias, such as the number of previous antidiabetic medi-
cines and comorbidity score [16].
The EMPRISE study—what have we learned so far?
The planned interim analysis of EMPRISE that was 
recently published covers data on HHF events with 
empagliflozin vs sitagliptin from August 2014 through 
September 2016, with a mean of 5.3  months follow-up 
[16]. The number of patients included in the analysis, 
after PS matching, was 16,443 for each treatment arm 
[16].
A balanced study population with a broad spectrum of CV 
risk
An assessment of standard deviation showed that base-
line characteristics between study arms were well bal-
anced [16], including various CV risk factors (Table  2). 
The number of previous antidiabetic medicines was 
equivalent between arms before, as well as after, PS-score 
matching, showing that both agents were typically used 
third line [16].
Laboratory results were available for only ~ 20% of 
patients [16], which we see as a limitation. However, key 
baseline characteristics in this subset of patients were 
well matched between study arms, including HbA1c, 
creatinine, cholesterol, LDL and HDL [16], even though 
these laboratory results were not used for PS match-
ing. Therefore, the covariates used in PS matching seem 
to have ensured well-balanced metabolic profiles across 
the full cohort, as expected from a previous study using 
the same PS-matching methodology [22]. The Hb1Ac 
balance between cohorts was further  confirmed by the 
similar levels seen between study arms even prior to PS 
matching [16].
The spectrum of CV risk was substantially broader than 
in CVOTs such as EMPA-REG OUTCOME, with 75% of 
patients with no reported history of CVD at baseline [7, 
16] (Table 2; in EMPA-REG OUTCOME, all patients had 
CVD at baseline, as stipulated in inclusion criteria [7]). 
Owing to PS matching, baseline rates remained equiva-
lent between study arms even when looking at individual 
components of CV risk, with coronary artery disease 
(CAD) the most prevalent (18%). Baseline prevalence 
a b
c
Fig. 1 SGLT2 inhibitors—what do guidelines say? a The EASD and the ADA jointly published a position statement on the management of 
hyperglycaemia in patients with T2D that were updated to reflect evidence from CVOTs. The revised treatment pathway, which recommends an 
early consideration of CV risk, is also now incorporated into the ADA’s Standards of Medical Care in Diabetes, which is for the first time endorsed by 
the ACC. Within a CV setting, the guidelines distinguish between atherosclerotic CVD, where empagliflozin or liraglutide are preferred as 2nd line to 
metformin, and HF, where any SGLT2 inhibitor is preferred in this position. b The ACC has recently published its own consensus pathway for CV risk 
reduction in patients with T2D and CVD, advising that agents with proven CV benefit are considered concurrently to metformin, with a preference 
for empagliflozin or liraglutide. c A separate guideline developed by the ACC jointly with the AHA addresses the primary prevention of CVD. In 
patients with T2D and CV risk factors, an SGLT2 inhibitor or GLP-1 RA is recommended as an early add-on to metformin. The guideline highlights 
evidence from CVOTs suggesting primary prevention of HF with SGLT2 inhibitors. ACC American College of Cardiology, ADA American Diabetes 
Association, AHA American Heart Association, CV cardiovascular, CVD CV disease, CVOT CV outcomes trial, EASD European Association for the Study 
of Diabetes, GLP-1 RA glucagon-like peptide-1 receptor agonist, HF heart failure, SGLT2 sodium–glucose transporter 2, T2D type 2 diabetes
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of heart failure was 5%, approximately half the value 
reported in EMPA-REG OUTCOME, although the iden-
tification of heart failure may have been inconsistent 
between studies [7, 16].
Results consistent with EMPA‑REG OUTCOME—but 
in a broader patient cohort
A comparison of HHF event rates between PS-matched 
treatment arms showed a 50% reduction in relative 
risk with empagliflozin vs sitagliptin (HR 0.50; 95% CI 
0.28–0.91) (Fig. 2a) [16]. We expected to see a reduction 
given the events reported for empagliflozin vs placebo in 
EMPA-REG OUTCOME (HR 0.65; 95% CI 0.50–0.85), 
but it was reassuring to see how consistent this effect was 
in a real-world setting and with a  more diverse patient 
population (Fig. 2a) [7, 16].
We were also encouraged to see such a robust result 
in a first interim analysis. Although already sufficiently 
powered for studying HHF events, the number of patients 
(32,886) is far smaller than the anticipated 200,000 by 
study completion [16]. Therefore, future analyses will 
provide even more evidence on HHF outcomes, and also 
be powered to shed light on rarer outcomes. The rapid 
emergence of an effect on HHF with empagliflozin, after 
a mean follow-up time of 5.3 months, is also consistent 
with EMPA-REG OUTCOME, where CV benefits vs pla-
cebo, including reduction in HHF, were apparent early in 
the study [11].
EMPRISE has provided an important opportu-
nity to observe CV outcomes with empagliflozin in 
patients without a history of CVD at baseline, who 
were not included in EMPA-REG OUTCOME [16]. As 
a first interim analysis, the study is not yet powered 
for detailed subgroup analyses, but current results do 
strongly point to a HHF benefit with empagliflozin 
that is consistent between patients with and without 
Table 1 Steps to minimise confounding in the EMPRISE study design
The EMPRISE study design used several approaches to minimise confounding [16], although undetected bias from residual confounding cannot be excluded. CVD 
cardiovascular disease, DPP-4 dipeptidyl peptidase-4, HF heart failure, HHF hospitalisation for HF, PS propensity score, SGLT2 sodium–glucose transporter 2
Minimising confounding
Key aspects of the EMPRISE study design
PS matching Patients are 1:1 matched with a “nearest neighbour” based on 140 predefined baseline characteristics 
(“covariates”)
Covariates include key factors relating to disease severity (such as # antidiabetic medications), comorbidities 
(such as CVD history) and many other clinical and demographic characteristics
Appropriate comparator choice The most commonly prescribed DPP-4 inhibitor is the chosen active comparator to empagliflozin, owing to 
the similar position of DPP-4 inhibitors to SGLT2 inhibitors in the treatment pathway
Using a comparator with a similar position is designed to maximise the similarity of disease severity 
between cohorts
No overlap between comparators Patients are excluded if they had received any SGLT2 inhibitor or DPP-4 inhibitor in the year preceding 
cohort entry, and follow-up is terminated if a patient switches to the comparator
Minimises the potential for immortal time bias
Sequential enrolment PS matching is performed independently for each enrolment
Ensures that study arms are balanced not just across the full cohort, but also for temporally matched popu-
lations
“As-treated” approach Follow-up captures only outcomes occurring during treatment exposure + 30 days
Minimises bias from confounding events not related to treatment
Assessing balance between cohorts
Data used to independently confirm robustness of PS matching approach
Baseline laboratory scores A range of laboratory scores at baseline are available for a subset of the population, including Hb1Ac, cho-
lesterol and creatinine levels
These scores are not used for PS matching, and so can provide an independent indication of equivalence 
between study arms
Sensitivity analyses
In each case, the conclusions regarding HHF benefit with empagliflozin were unchanged
High-dimensional PS matching PS matching with 100 additional covariates
Alternative comparator The sitagliptin cohort is replaced with a cohort composed of patients receiving any DPP-4 inhibitor
Subgroup analyses Subgroup analyses include:
 With/without CVD at baseline
 With/without HF at baseline
 Gender
 Empagliflozin dose
Alternative HHF definition Broadening the definition of HHF from hospitalisation with HF in the primary discharge position to hospitali-
sation with HF in any discharge position
Control outcome An outcome with an expected null finding (flu vaccination)
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CVD at baseline [16]. We must therefore consider that 
the clinical and cost implications of reducing HHF 
with empagliflozin may extend beyond the patient pro-
file of EMPA-REG OUTCOME to also include those 
without clinical evidence of CVD.
How robust is the HHF benefit with empagliflozin?
To ensure that the study design has not biased RWE find-
ings, it is important to ensure that conclusions are robust 
to alternative parameter selections and inclusion criteria. 
Additional analyses of the interim EMPRISE data showed 
Table 2 Key baseline characteristics in the 8/2014–9/2016 EMPRISE cohort
Baseline characteristics confirmed the success of creating balanced study arms in the first interim EMPRISE analysis [16]. Cohorts had equivalent scores for a wide 
range of factors, including CV risk factors; shown here are scores for some key characteristics of interest. Treatment history was included in the PS score to ensure that 
treatment position was considered during matching. However, the similar treatment histories and HbA1c scores even prior to PS matching confirm that the active 
comparator was appropriately chosen as in an equivalent position in the treatment pathway to empagliflozin. CAD coronary artery disease, CV cardiovascular, CVD CV 
disease, HF heart failure, PAD peripheral artery disease, PS propensity score










PS matching # antidiabetic drugs (mean) 2.2 2.3 2.2 2.2
 Treatment naïve (%) 13% 7% 8% 8%
CV risk factors
 Any CVD (%) 37% 24% 25% 25%
 CAD (%) 26% 18% 18% 18%
 Stroke (%) 10% 5% 6% 6%
 PAD (%) 10% 5% 5% 5%
 HF (%) 11% 5% 5% 5%
Lab results (not used for PS matching)
 HbA1c (mean) 8.3 8.5 8.6 8.5
a b
Fig. 2 HHF events in EMPRISE and EMPA-REG OUTCOME. a The relative risk reduction of HHF in the first interim analysis of EMPRISE was consistent 
with that seen in EMPA-REG OUTCOME, confirming the robustness of empagliflozin’s HHF benefit in routine clinical practice, in a population with 
a broader CV risk profile, and against a DPP-4 inhibitor as an active comparator. b The first interim analysis of EMPRISE had a primary analysis of 
hospitalisation events with discharge diagnosis of HF in the primary position compared between empagliflozin and sitagliptin. However, secondary 
analyses showed that the HHF benefit with empagliflozin was robust even when using a broader definition of HHF (discharge diagnosis of HF in any 
position) or broadening the active comparator to include all DPP-4 inhibitors, not just sitagliptin. CV cardiovascular, DPP-4 dipeptidyl peptidase-4, HF 
heart failure, HHF hospitalisation for HF
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that including all DPP-4 inhibitor agents in the com-
parator arm or using a broader definition for HHF did 
not have a meaningful effect on outcomes [16] (Fig. 2b). 
These additional analyses provide reassurance that the 
conclusion of HHF benefit with empagliflozin vs DPP-4 
inhibitors is robust.
EMPRISE in context—where does RWE fit 
in the bigger CVOT picture?
The key CV benefits shown in EMPA-REG OUT-
COME were reduced risks of CV death and HHF [7]. 
More broadly, SGLT2 inhibitor CVOTs have consist-
ently shown a reduced risk of HHF vs placebo, whereas 
a reduction in CV death has thus far been unique to 
empagliflozin [7–9]. Consequently, important questions 
remain about class effect with SGLT2 inhibitors that 
RWE may help to address.
Heart failure
EMPRISE adds to accumulating evidence from SGLT2 
inhibitor CVOTs that HF benefits include primary as 
well as secondary prevention [7–9]. These findings are 
also consistent with the recent CREDENCE trial of cana-
gliflozin in patients with T2D and chronic kidney dis-
ease (CKD) [23], and earlier RWE studies that compared 
SGLT2 inhibitors as a class with all other glucose-lower-
ing drugs [24–26].
The effect size observed across all studies is consist-
ently impressive, typically 30–40% in the RCTs [7–9, 23] 
and 40–50% in the RWE studies [16, 24, 25]. Further-
more, these studies collectively show that HHF is reduced 
in a broad spectrum of patients with T2D, consistently 
including those without a prior history of HF. Therefore, 
there is considerable and wide-ranging evidence for sub-
stantial primary and secondary prevention of HHF. As 
such, new American Heart Association (AHA)–Ameri-
can College of Cardiology (ACC) guidelines on the pri-
mary prevention of CVD recommend SGLT2 inhibitors 
as an early add-on to metformin in patients with T2D and 
CV risk factors (Fig. 1c), citing HHF reductions reported 
in CVOTs even for primary prevention populations [5].
HHF events in EMPA-REG OUTCOME occurred 
in a less diverse population than is seen for real-world 
HHF events [27]. EMPRISE is now providing insights 
into HHF outcomes in a broader population with T2D, 
while numerous ongoing RCTs will assess SGLT2 inhibi-
tors specifically in a HF setting [28], including in patients 
without T2D, and we look forward to understanding 
more about the impact of these agents on HF once data 
become available.
CV death
While HHF benefit seems to be a consistent observation 
with SGLT2 inhibitors in patients with T2D, empagliflo-
zin remains the only SGLT2 inhibitor proven to reduce 
CV death (38% reduction in EMPA-REG OUTCOME 
[7]). Although canagliflozin did show a trend towards 
a reduction in both the CANVAS Program and CRE-
DENCE, this did not meet significance [8, 23], while there 
was no apparent effect with dapagliflozin in DECLARE-
TIMI 58 [9]. Empagliflozin is also the only agent in the 
class proven to reduce death by any cause, with a 32% 
reduction in EMPA-REG OUTCOME, but this is unsur-
prising given that the CV death component was the main 
driver of this benefit [7].
We do not yet know whether the inconsistent CV death 
outcomes between agents is due to intrinsic differences 
in treatment effects or differences in patient populations 
and study designs, such as the CV risk profile at baseline. 
In EMPA-REG OUTCOME, inclusion criteria dictated 
that all patients should have overt CVD, either as a diag-
nosis of CAD or a history of MI or stroke [7]. The CAN-
VAS Program and DECLARE-TIMI 58 also included 
such patients, but additionally enrolled patients with 
multiple CV risk factors, such as dyslipidaemia, smoking 
or hypertension [8, 9].
Subgroup analyses have shown that no significant 
reduction in CV death was seen in the CANVAS Pro-
gram and DECLARE-TIMI even when considering only 
patients with baseline CVD [8, 9, 29]. Similarly, no sig-
nificant reduction in CV death was seen in patients with 
prior MI in DECLARE-TIMI 58 [30] or patients with cer-
ebrovascular disease in the CANVAS Program [31].
As a renal study rather than a CVOT, CREDENCE did 
not have any requirements for CV risk in patient enrol-
ment, but nevertheless reported a 50% prevalence of 
CVD at baseline, and so included a sizeable cohort of at-
risk patients [23]. An analysis of CV death in subgroups 
with and without baseline CVD has not been reported 
for this study; however, the primary outcome, which was 
a composite of CV death and several nephropathy out-
comes, had a near identical response to treatment in both 
subgroups [23].
Therefore, current evidence suggests that differences 
in CVD prevalence between study cohorts cannot read-
ily account for the reduction of CV death in EMPA-REG 
OUTCOME but not other SGLT2 inhibitor CVOTs. By 
including a broader CV risk population than EMPA-REG 
OUTCOME, future results from EMPRISE will provide 
important context to our understanding of CV death 
reductions with empagliflozin.
Similarly to CVD, renal disease is prevalent as a major 
mortality risk in patients with T2D [32, 33]. However, dif-
ferences in renal populations also cannot convincingly 
Page 7 of 9Schernthaner et al. Cardiovasc Diabetol          (2019) 18:115 
explain the inconsistent CV death results. A renal sub-
group analysis of EMPA-REG OUTCOME showed 
that the effect of empagliflozin on CV death did not 
increase with declining baseline renal function, suggest-
ing that reduced renal function was not a key driver of 
treatment benefit [34]. A similar subgroup analysis of 
DECLARE-TIMI 58 also showed a lack of interaction 
between renal risk and CV death, with dapagliflozin pro-
ducing a seemingly neutral effect in all renal risk groups 
[9], while the baseline renal risk profile of the CANVAS 
Program cohort was similar to EMPA-REG OUTCOME, 
and not linked to CV outcomes [34, 35]. More recently, 
the CREDENCE study, in which the majority of patients 
had reduced renal function, showed that canagliflozin 
narrowly missed statistical significance for reducing CV 
death even in this at-risk group of patients [23].
Therefore, CV death outcomes cannot easily be 
ascribed to differences in either CVD or renal profiles 
at baseline. As such, the class effect question remains a 
pertinent one, and any further light that future EMPRISE 
results can shed on CV death outcomes with empagliflo-
zin will be of great interest.
Guidelines
The first EMPRISE results [16] are consistent with recent 
guideline updates (Fig.  1a) [1, 3] in showing that empa-
gliflozin may be preferred to DPP-4 inhibitors where the 
goal is to reduce HHF events. EMPRISE also supports 
the recent AHA and ACC recommendation [5] favouring 
SGLT2 inhibitors for primary prevention of HF in patients 
with T2D (Fig. 1c), although evidence from ongoing dedi-
cated HF RCTs [28] may be required before other guide-
lines and reimbursement decisions will follow suit. Future 
insights from EMPRISE will provide welcome guidance 
on the implications of empagliflozin vs DPP-4 inhibitor 
use in patients for whom guidelines do not express a pref-
erence, including real-world effectiveness patterns and 
savings in healthcare resource utilisation and cost.
Future data releases—what to look for in safety 
and health economic outcomes
Safety
While the safety profile of empagliflozin in clinical stud-
ies has been generally favourable [7, 36], rare events 
may only be detectable in a larger cohort, such as that 
provided by EMPRISE. This will add to reassurances on 
safety with SGLT2 inhibitors in routine clinical practice 
provided by previous RWE studies, such as the CVD-
REAL programme, which compared SGLT2 inhibitors as 
a class with all other glucose-lowering drugs [24–26]. For 
example, CVD-REAL has shown that SGLT2 inhibitors 
do not increase the risk of MI and stroke outcomes, con-
sistent with CVOT findings [37]. Accumulating evidence 
for rare events of DKA with SGLT2 inhibitors [23, 29] has 
led to a warning on product labels advising alertness for 
this potentially dangerous event, and its atypical presen-
tation in patients with only moderately increased blood 
glucose [38]. By study completion, EMPRISE should pro-
vide evidence from a cohort of 200,000 patients [16] to 
improve our understanding of this rare event and which 
patients are most at risk. Furthermore, confirming the 
safety profile of empagliflozin vs DPP-4 inhibitors in the 
diverse patients seen in clinical practice will reassure cli-
nicians who are seeking a suitable alternative to DPP-4 
inhibitors in a CVD setting.
Healthcare resource utilisation
For many of us, the barrier posed by reimbursement 
requirements is a major driver of treatment choice. We 
expect that reducing HHF with SGLT2 inhibitors has the 
potential to generate resource and cost savings to health 
systems, as hospitalisation is responsible for a substantial 
proportion of the lifetime costs of HF management [39]. 
We look forward to EMPRISE results on health economic 
outcomes that will quantify these savings for various 
aspects of resource utilisation.
Conclusions
We are commonly faced with a treatment choice between 
SGLT2 inhibitors and DPP-4 inhibitors in the manage-
ment of T2D, in patients with a spectrum of CV risk. 
Early results from EMPRISE can already begin to inform 
such treatment choices, confirming that the HHF benefit 
with empagliflozin in EMPA-REG OUTCOME translates 
to a comparison with DPP-4 inhibitors in a real-world 
population. Future data releases will provide additional 
insights on other effectiveness outcomes, as well as safety 
and health economic outcomes.
While RWE is inevitably limited by the possibility of 
residual confounding [16], we welcome the careful atten-
tion paid by the authors of EMPRISE to minimise possi-
ble sources of bias [16], such as the steps taken to address 
concerns relating to immortal time bias that have been 
raised with previous RWE studies [19–21], providing 
more confidence in its results.
The role of RWE in complementing CVOTs is increas-
ingly being recognised, including by regulatory bodies 
such as the US FDA, NICE in the UK, and the German 
IQWiG [10]. Despite the unavoidable limitations asso-
ciated with RWE studies, the advantages of a cohort of 
200,000 patients cannot be denied, and such a large-scale 
study would not be feasible under RCT conditions. It is 
hoped that this large cohort will provide additional con-
text to CVOT-generated insights into CV protection with 
empagliflozin.
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